Overviews
TCF7L2
CDKAL1, PPARG, and CDKN2A
Prevention
Overviews
American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31 Suppl 1:S12-54.
Janssens AC, Gwinn M, Valdez R, Narayan KM, Khoury MJ. Predictive genetic testing for type 2 diabetes. BMJ. 2006;333(7567):509-510.
Todd JA. Statistical false positive or true disease pathway? Nat Genet.2007;38(7)::731-733.
Weedon MN, McCarthy MI, Hitman G, et al. Combining Information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med. 2006;3(10):e374.
TCF7L2
Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program. N Engl J Med.2006;355(3):241-250.
Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320-323.
Helgason A, Palsson S, Thorleifsson G, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet. 2007;39(2):218-225.
Munoz J, Lok KH, Gower BA, et al. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes. 2006;55:3630-3634.
Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, Hattersley AT, Morris AD, Palmer CN. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes. 2007;56(8):2178-82.
Smith U. TCF7L2 and type 2 diabetes -- we WNT to know. Diabetologia. 2007;50(1):5-7.
Saxena R, Gianniny L, Burtt NP, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes. 2006;55(10):2890-2895.
Weedon MN. The importance of TCF7L2. Diabet Med. 2007;24(10):1062-6.
Zeggini E, McCarthy MI. TCF7L2: The biggest story in diabetes genetics since HLA? Diabetologia. 2007;50(1):1-14.
Zhang C, Qi L, Hunter DJ, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. Diabetes. 2006;55(9):3645-3648.
CDKAL1, PPARG, and CDKN2A
Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26(1):76-80.
Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20(3):284-7.
Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, et al. Genome-wide detection and characterization of positive selection in human populations. Nature. 2007;449(7164):913-8.
Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007;316(5829):1341-5.
Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet. 2007;39(6):770-5.
Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316(5829):1336-41.
Prevention
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med. 2002;346(6):393-405.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096-105.
NIDDK:NDIC. Diabetes Prevention Program. Available at: http://diabetes.niddk.nih.gov/dm/pubs/preventionprogram/. Accessed: July 18, 2008.